Sign inJoin waitlistJoin the waitlist

Jing Zeng

Vice Chair of Clinical Affairs, Department of Radiation Oncology, UW Medicine · University of Washington School of Medicine

Credentials: · · ·

History

Department of Radiation Oncology · University of Washington School of Medicine
Present
University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Radiation Oncology
Johns Hopkins University School of Medicine
2008–2012
Mercy Medical Center Internship 2008
2007–2008
Duke University School of Medicine
2003–2007
Johns Hopkins University
1999–2003

Research

Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas
International journal of radiation oncology · 2013 · First of 21 authors · 737 citations
Targeting DDX3 with a small molecule inhibitor for lung cancer therapy
EMBO Molecular Medicine · 2015 · 204 citations
Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model
PLoS ONE · 2014 · 196 citations

Ramesh Rengan
36 papers
Hubert Vesselle
12 papers
GK
Gabrielle Kane
11 papers
Phuoc Tran
10 papers
Jay Liao
9 papers
Smith Apisarnthanarax
8 papers
CS
Charles Simone
7 papers
SP
Shilpen Patel
7 papers
Avrey Novak
6 papers
Henry Tsai
6 papers
HL
Howard Lee
6 papers · 3 as a fellow
Jonathan Chen
6 papers

Grants

Biomarkers of Response to Immuno-Chemotherapy & oliGometastatic Hypofractionated radioTherapy (BRIGHT) for Lung Cancer: Synergy of PET/CT Imaging and Peripheral Blood Assays
National Cancer Institute · R01
PI · $2.8M · University of Washington
2021–2027
Personalized Radiation Therapy Through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio
National Cancer Institute · R01
PI · $2.3M · University of Washington
2016–2021

Clinical trials

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
Principal investigator · Withdrawn · Phase 2
University of Washington
2023–2024
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
Principal investigator · Terminated · Phase 2
University of Washington
2021–2022
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
Principal investigator · Terminated · Phase 2
University of Washington
2020–2023
Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma
Principal investigator · Terminated · Phase 2
University of Washington
2019–2024